Fifteen% or fewer of patients with non-small cell lung cancer (NSCLC) survive 5 years. The
current standard of care for patients with locally advanced or metastatic NSCLC is systemic …

Lung cancer is the most common cause of cancer death. The vast majority of patients
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …

Non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths in the USA
and worldwide. Most patients present with advanced disease, and treatment options for …

The Epidermal Growth Factor Receptor (EGFR) family, including EGFR, HER2, HER3, and
HER4, is implicated in the development and progression of cancer, and is expressed in …

Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major
forms of lung cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancers …

Although chemotherapy remains the standard of care for lung cancer, new less toxic drugs
are urgently needed. Targeted agents represent a new era in cancer therapy, and non …

Epidermal growth factor receptor (EGFR) inhibitors have introduced the concept of targeted
therapy to the treatment of non‐small cell lung cancer (NSCLC). These agents appear most …

Molecularly targeted therapies have recently expanded the options available for patients
with advanced non-small-cell lung cancer (NSCLC). Two cancer cell pathways in particular …

Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Non–small cell lung cancer (NSCLC) is the leading cause of cancer death in the United
States and throughout the world. This is largely because more than half of lung cancer cases …